Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten‐year experience at a single center

Cartin‐Ceba, Rodrigo, Golbin, Jason M., Keogh, Karina A., Peikert, Tobias, Sánchez‐Menéndez, Marta, Ytterberg, Steven R., Fervenza, Fernando C., Specks, Ulrich·2012·Arthritis & Rheumatism

Abstract

Objective: This study was conducted to evaluate the efficacy and safety of repeated and prolonged B cell depletion with rituximab (RTX) for the maintenance of long‐term remission in patients with chronic relapsing granulomatosis with polyangiitis (Wegener's) (GPA). Methods: We conducted a single‐center observational study of all patients with chronic relapsing GPA treated with at least 2 courses of RTX between January 1, 2000 and May 31, 2010. Participants in the Rituximab in ANCA‐Associated Vasculitis (RAVE) trial were excluded from this analysis. Data were abstracted from electronic medical records. Results: Fifty‐three patients with refractory GPA (median age 46 years [interquartile range (IQR) 30–61 years]; 53% women) received at least 2 courses of RTX to treat GPA relapses or to maintain remission. All but 1 patient had antineutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3). These patients received a median of 4 courses of RTX (IQR 3–5); all had depletion of B cells, and the median time to return of B cells was 8.5 months (IQR 6–11 months). All observed relapses occurred after reconstitution of B cells and were accompanied or preceded by an increase in ANCA levels, except for the 1 ANCA‐negative patient. Infusion‐related adverse events occurred in 16 patients. During the period of B cell depletion, 30 infections requiring antimicrobial therapy were recorded. Conclusion: RTX appeared to be effective and safe for the induction and maintenance of remission in patients with chronic relapsing GPA. Repeated depletion of B lymphocytes seems to be associated with a low risk of infections. Preemptive re‐treatment decisions can be individualized based on serial B lymphocyte and PR3 ANCA monitoring. The use of RTX for the maintenance of long‐term remission merits further formal investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34584

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 291

Metadata

Authors
Cartin‐Ceba, R., Golbin, J. M., Keogh, K. A., Peikert, T., Sánchez‐Menéndez, M., Ytterberg, S. R., Fervenza, F. C., & Specks, U.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-10-27
Volume
64
Issue
11
Pages
3770-3778
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2007778318
Cited by
291
References
30
FWCI
32.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten‐year experience at a single center. https://app.cochat.ai/papers/10.1002/art.34584
The paper
Cartin‐Ceba, R., Golbin, J. M., Keogh, K. A., Peikert, T., Sánchez‐Menéndez, M., Ytterberg, S. R., Fervenza, F. C., & Specks, U. (2012). Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten‐year experience at a single center. Arthritis & Rheumatism. https://doi.org/10.1002/art.34584

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.